Xiangya Medical Laboratory of Central South University was established on the basis of Institute of Clinical Pharmacology and Institute of Genetic Pharmacology of Central South University. After decades of efforts by Academician Zhou, there are 14 national and provincial technical platforms, such as "National Innovation Service Platform for Pharmaceutical Genome Application Technology", which can provide strong technical support for the smooth development of research projects. The laboratory has more than 2000 square meters of professional laboratories, including clinical pathology room, clinical immunology room, clinical gene amplification laboratory, clinical biochemistry room, clinical microbiology room, TDM laboratory and other professional laboratories, equipped with advanced instruments and equipment. The laboratory is established in strict accordance with the Basic Standards for Medical Laboratory promulgated by the Ministry of Health, with advanced management team, professional technical team, experienced marketing team, enthusiastic and sincere customer service team and authoritative experts at home and abroad.

1) National Medical Genome Application Technology Innovation Service Platform

20 10 passed the examination and approval of the Ministry of Science and Technology, and integrated high-quality resources such as talents, technology, equipment and information in the field of pharmacogenomics research, providing public services such as individualized medical gene testing, medication scheme design, information, standards and intellectual property rights for new drug research enterprises and medical institutions; Industry-University-Research jointly develops new drug research and development and clinical individualized safe and rational drug use; Industrialization and engineering of previous research results related to drug genome; Accelerate the promotion of advanced and applicable technologies and new products to pharmaceutical enterprises and clinical medical institutions.

2) National Science and Technology Major Project-Key Technology Platform for Drug Safety Evaluation

With the support of major national science and technology projects, the research platform of China people's drug metabolizing enzyme gene polymorphism and its functional differences was established, and the database of drug metabolizing enzyme gene polymorphism distribution, enzyme activity and gene polymorphism detection technology was established, which provided technical support for screening patients with drug-specific reactions and clinical safe medication.

3) Research platform of 863 key project "genome-wide association studies of major diseases and pharmacogenomics research"

Taking the common major diseases that threaten the health of Chinese people as a breakthrough, through the research of genome-wide association studies and pharmacogenomics, this paper expounds the genetic mechanism of disease onset, the relationship between pharmacogenomics-related gene polymorphism and drug efficacy and safety, and finds the genetic markers and early warning targets of new drugs and diseases, so as to provide theoretical basis, technical support and talent reserve for the diagnosis, prevention and safe and effective drug use of Chinese people.

4) Research Center of Pharmaceutical Genome Application Technology Engineering, Ministry of Education

Approved by the Ministry of Education in 2007, it is a pharmaceutical genome application technology engineering research center with world advanced level and comprehensive development and research functions. Committed to the research and development of personalized drug gene chips for nine diseases such as hypertension, diabetes, psychosis, malignant tumor, ulcer and hyperlipidemia, build a production base that meets GMP requirements, and form special software and products with independent intellectual property rights. Popularize the theoretical knowledge of individualized medication and the genetic testing products of individualized medication, so as to achieve the purpose of safe and rational medication for the people; Cooperate with pharmaceutical companies to develop new drugs that match the genetic test results of individual drug therapy.

5) American Traditional Chinese Medicine Foundation-Asia Demonstration Laboratory of Genetics and Pharmacology of Central South University

1999 was jointly established by China Medical Committee (CMB) and the Genetics and Pharmacology Laboratory of Central South University. Using the operation mechanism of China Merchants Bank and Central South University, a genetics and pharmacology laboratory was established. CMB Asia Genetics Pharmacology Demonstration Laboratory is the Asian Genetics Pharmacology Center, which aims to promote the development of genetics pharmacology in Asia as a whole and train professionals in genetics pharmacology for Asian countries and other countries.

6) Asia Center of International Advocacy Organization for Genetics and Pharmacology

Founded in 2009 by the National Institutes of Health (NIH) and the Bill Gates Foundation, it is headquartered in the Center for Individualized Drug Therapy and Pharmacogenomics of the University of North Carolina School of Medicine. * * * There are 104 countries participating in the world, and seven centers have been established around the world. The Institute of Clinical Pharmacology of Central South University is the only center of PGENI in East Asia. It aims to fund the safe and individualized medication of multi-ethnic groups around the world, and integrate pharmacogenomics information into the management decisions of the National Public Health and Drug Administration.

7) National Drug Clinical Research Base of US Food and Drug Administration

In 2005, the National Drug Clinical Research Base passed SFDA certification. It is an authoritative base for national-level phase I clinical trials of new drugs, clinical pharmacokinetics research of new drugs and its technical consultation and service, data management and statistical analysis, and (genetic) pharmacokinetics research based on pharmacogenomics.

8) National Clinical Pharmacology Training Center of the Ministry of Health

Founded in the early 1980s, it is the first national clinical pharmacology training center in China. Up to now, 26 training courses have been held in China, and more than 3,000 senior talents in drug clinical trials and drug clinical research have been delivered, aiming at popularizing the standardization of drug research and individualization of clinical medication.

9) Individualized Drug Counseling and Guidance Center of Hunan Province

Hunan Provincial Health Department was approved to be established in June 2004, with experts 1 1 person. Co-founded by the Institute of Clinical Pharmacology of Central South University and the Third Xiangya Hospital of Central South University, it is the first provincial-level individualized drug therapy consultation and guidance center in China. The center applies internationally influential scientific research achievements in pharmacogenetics and pharmacogenomics to individualized drug therapy, guides clinical medication, and provides services for improving the national level of rational drug use and clinical medication safety.

10) Hunan Key Laboratory of Genetics and Pharmacology

20 10 officially passed the acceptance of Hunan science and technology department in February. It is an internationally influential individualized medical research base, a training base for senior professionals and a radiation base for transforming high-tech achievements. It has obvious advantages and characteristics in the study of genetic variation and susceptibility of major diseases and the mechanism of their differences with drugs, as well as the study of the genetic pharmacology basis and clinical application of traditional Chinese medicine and natural medicine.

1 1) Hunan biochip industry strategic alliance technology innovation platform

20 10 Industry-University-Research Technology Innovation Platform was officially approved by Hunan Science and Technology Department in May. Led by the Institute of Clinical Pharmacology of Central South University, it is jointly established by universities, enterprises, scientific research institutes and medical institutions with a good foundation in biochip technology research, product development and industrialization. The main task of the alliance is to develop biochips for individualized gene diagnosis and individualized gene targeted therapy. The development of this chip will greatly promote the development of individualized medical care in China.

12) Central South University drug screening transgenic cells in vitro research platform.

The most authoritative recombinant cell platform for stable expression of drug metabolizing enzyme SNPs in China has been established with the support of "Drug Safety Evaluation", which can be used to measure and compare the pharmacokinetic differences between different SNPs in vitro, screen and predict the preclinical metabolic properties of innovative drugs or new drug lead compounds, and provide scientific basis for clinical potential drug safety evaluation.

13) Central South University genetic pharmacokinetics drug analysis and detection technology platform

The national platform for drug analysis and detection of gene drug metabolism kinetics has the most advanced in-vitro and in-vivo drug concentration monitoring and analysis instruments in China, a doctor technical team with rich experience in drug analysis, and a first-class therapeutic drug monitoring (TDM) technical force in China.

14) Central South University pharmacogenetics and pharmacogenomics information platform.

The first information search platform for safe and rational drug use in China promotes the development of China's medical cause, provides a useful information base with China national characteristics for the world's biological resources, and serves as an information resource platform for the transformation and application of pharmacogenomics.